CURASIGHT A/S
NNGM:CURAS8.78
DKK
-0.30
(-3.30%)
ISIN
DK0061295797
Return %
Stock
S&P 500
1Y
86.81
14.20
3Y
-19.95
81.12
5Y
-33.52
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Ulrich A. Krasilnikoff
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Copenhagen Denmark
- IPO Date
- Sep 15, 2020
- Website
- curasight.com
- Similar Companies
- Business
- Curasight A/S is a clinical-stage biotechnology company that develops targeted theranostic solutions for cancer diagnosis and radionuclide therapy. Founded in 2013 and headquartered in Copenhagen, Denmark, the company operates in the biopharmaceutical and molecular diagnostics sector, focusing on the urokinase-type plasminogen activator receptor (uPAR) biomarker platform to advance personalized oncology care. The company’s core product and technology offerings comprise: uTRACE, a non-invasive diagnostic positron emission tomography (PET) imaging platform utilizing the radiolabeled peptide 64Cu-DOTA-AE105 for precise tumor visualization, risk stratification, and patient selection across multiple oncology indications including prostate cancer, brain cancer (glioblastoma), head and neck cancer, breast cancer, and neuroendocrine tumors; and uTREAT, a targeted radioligand therapeutic platform utilizing the beta-emitting radiopharmaceutical 177Lu-DOTA-AE105 to deliver localized radiation directly to uPAR-expressing malignant cells to achieve targeted tumor cell destruction while sparing surrounding healthy tissue. Curasight serves the global oncology and molecular diagnostics market, conducting clinical trials and research operations across Denmark, broader Europe, and the United States. In recent developments, Curasight established an exclusive global license and collaboration partnership with Curium for the clinical development and commercialization of uTRACE in prostate cancer, providing potential development and commercial milestone payments along with tiered royalties. In addition, the company has advanced its clinical and preclinical development programs for uTREAT targeting glioblastoma and neuroendocrine neoplasms, successfully completed capital raising initiatives through rights issues and warrant subscription programs to fund clinical trials, and expanded its international intellectual property portfolio covering uPAR-targeted theranostics.